drugset / Trial / NCT01238055
Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether Sunitinib and Docetaxel is effective in the treatment of advanced gastric cancer patients who had prior chemotherapy with fluoropyrimidine and platinum.
Timeline
- Start
- 2008-11
- Primary completion
- 2012-04
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Sunitinib | Small molecule | 37.5 mg | — |